Rancho Cordova, California, USA, August 21, 2026
SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced its participation in CPHI Milan, where the company will showcase its expanding multimodal capabilities and global pharmaceutical manufacturing infrastructure. The event is scheduled for October 8–10, 2026, in Milan, Italy, with SK pharmteco’s management, sales, and technical teams available at Booth 10A25. The company will highlight integrated, end-to-end development and manufacturing solutions designed to support pharmaceutical and biopharmaceutical programs from early clinical development through commercial-scale production. The announcement also emphasizes SK pharmteco’s commitment to sustainability across the pharmaceutical supply chain through its role as an official sponsor of the CPHI Sustainability Summit and Sustainability Theater.
Multimodal CDMO Capabilities Support Drug Development
At CPHI Milan, SK pharmteco will demonstrate how its global network across North America, Europe, and Asia supports customers developing complex pharmaceutical products. A major focus will be its small-molecule and advanced-intermediate capabilities, which include development and manufacturing of active pharmaceutical ingredients (APIs), regulatory starting materials, advanced intermediates, and high-potency APIs. The company’s manufacturing capabilities extend from gram-scale development to multi-tonne commercial production, enabling pharmaceutical programs to progress from early development into established commercial supply. This integrated approach is intended to help biopharmaceutical companies manage development requirements while maintaining consistent quality and reliable manufacturing capacity throughout the product lifecycle.
Peptide and Viral Vector Manufacturing Expand
SK pharmteco will also highlight its growing peptide development and manufacturing services, which complement its established small-molecule capabilities. These services cover process development, scale-up, clinical manufacturing, and commercial production, with an emphasis on process robustness, quality consistency, and dependable supply. The company will additionally showcase its SKyvec™ viral vector platform, which is designed to support process development, manufacturing, and scale-up for AAV, lentiviral, and adenoviral vectors. Through these capabilities, SK pharmteco supports developers working on rare disease therapies at different stages of development, from early process work and clinical manufacturing to planning for larger-scale production and future supply requirements. The combination of small molecules, peptides, and viral vectors positions the CDMO to support multiple therapeutic modalities within a single global manufacturing network.
Advertisement
Global Supply Chain and Sustainable Manufacturing
Another central theme of SK pharmteco’s CPHI presence will be global supply-chain resilience. The company says its manufacturing infrastructure across the United States, Europe, and Korea provides pharmaceutical and biopharmaceutical partners with supply options intended to reduce development risks and support uninterrupted product availability. Its business development and technical leadership teams will be available during the event for discussions covering tailored development programs, manufacturing capacity, and technical consultations. Alongside its manufacturing activities, SK pharmteco’s sponsorship of the CPHI Sustainability Summit and Sustainability Theater highlights the company’s focus on environmental protection and sustainable pharmaceutical operations. By bringing together its small-molecule, peptide, viral-vector, and supply-chain capabilities, SK pharmteco aims to demonstrate how a multimodal CDMO model can help pharmaceutical companies move complex therapies from development toward commercialization while maintaining quality, scalability, and supply reliability.
Source: SK pharmteco press relese
